Switch to:
Also traded in: Germany, Japan
» Details

Insider Trades

Latest Guru Trades with ALPMY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major  
Compare:OTCPK:OTSKY, OTCPK:CHGCY, OTCPK:DSNKY, OTCPK:OPHLY, OTCPK:KYKOF, OTCPK:CHJTF, OTCPK:SNPHY, OTCPK:PTKFY, OTCPK:GWPRF, NAS:HCM, OTCPK:MAYNF, OTCPK:HAWPF, NAS:AERI, AMEX:TXMD, NAS:RTRX, NAS:ASMB, NAS:RMTI, NAS:NBRV, NAS:ZGNX, OTCPK:AGYTF » details
Traded in other countries:YPH.Germany, 4503.Japan,
Astellas Pharma Inc and its subsidiaries are engaged in manufacturing, marketing and import/export of pharmaceuticals. It develops products in the areas of urology, immunology and allergy, cardiovascular, diabetes, gastrointestinal and motor organs.

Astellas Pharma Inc was incorporated on March 20, 1939. The Company and its subsidiaries are engaged in the manufacturing, marketing of pharmaceuticals products. It develops products in the areas of urology, immunology and allergy, cardiovascular, diabetes, gastrointestinal and motor organs. Its products include Prograf, an immunosuppressant to prevent rejection in organ transplants; Protopic for the treatment of atopic dermatitis in the topical immunomodulator class; Vesicare, a treatment for overactive bladder; Harnal, an a1 blocking agent for the treatment of benign prostatic hyperplasia; and Funguard, a candin antifungal agent. The Company's products also comprise Geninax, an oral quinolone antibacterial agent; Celecox, a selective COX-2 inhibitor; Lipitor, a treatment for hypercholesterolemia; Micardis, a treatment hypertension; Gaster, a treatment for peptic ulcers and gastritis; Myslee, a hypnotic; Cefzon, an oral cephalosporin; Seroquel, an antipsychotic agent; Dorner, a treatment for chronic arterial occlusion; Nasea, an antagonist; Regnite, a treatment for restless legs syndrome; and Kiklin, a treatment for hyperphatemia. The Company also offers Lexiscan and Adenoscan, which are pharmacologic stress agents; Tarceva, a treatment for non-small cell lung cancer; Vaprisol, a treatment for euvolemic hyponatremia; AmBisome, a systemic antifungal agent; Eligard, a treatment for advanced prostate cancer; Locoid, a topical corticosteroid; Zineryt, a treatment for acne; Locobase, a treatment for dry skin; and Dificlir, a novel treatment for CDI.

Ratios

vs
industry
vs
history
PE Ratio 15.64
ALPMY's PE Ratio is ranked higher than
79% of the 568 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.40 vs. ALPMY: 15.64 )
Ranked among companies with meaningful PE Ratio only.
ALPMY' s PE Ratio Range Over the Past 10 Years
Min: 3.3  Med: 15.99 Max: 104.4
Current: 15.64
3.3
104.4
PE Ratio without NRI 15.64
ALPMY's PE Ratio without NRI is ranked higher than
79% of the 543 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.84 vs. ALPMY: 15.64 )
Ranked among companies with meaningful PE Ratio without NRI only.
ALPMY' s PE Ratio without NRI Range Over the Past 10 Years
Min: 3.3  Med: 15.99 Max: 104.45
Current: 15.64
3.3
104.45
Price-to-Owner-Earnings 16.17
ALPMY's Price-to-Owner-Earnings is ranked higher than
79% of the 300 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 34.72 vs. ALPMY: 16.17 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ALPMY' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 5.69  Med: 25.54 Max: 152.22
Current: 16.17
5.69
152.22
PB Ratio 2.42
ALPMY's PB Ratio is ranked higher than
61% of the 827 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.02 vs. ALPMY: 2.42 )
Ranked among companies with meaningful PB Ratio only.
ALPMY' s PB Ratio Range Over the Past 10 Years
Min: 1.27  Med: 2 Max: 3.37
Current: 2.42
1.27
3.37
PS Ratio 2.50
ALPMY's PS Ratio is ranked higher than
57% of the 766 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.06 vs. ALPMY: 2.50 )
Ranked among companies with meaningful PS Ratio only.
ALPMY' s PS Ratio Range Over the Past 10 Years
Min: 0.61  Med: 2.23 Max: 10.2
Current: 2.5
0.61
10.2
Price-to-Free-Cash-Flow 12.83
ALPMY's Price-to-Free-Cash-Flow is ranked higher than
75% of the 226 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 22.72 vs. ALPMY: 12.83 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ALPMY' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 12.36  Med: 26.24 Max: 81.38
Current: 12.83
12.36
81.38
Price-to-Operating-Cash-Flow 10.06
ALPMY's Price-to-Operating-Cash-Flow is ranked higher than
75% of the 295 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.98 vs. ALPMY: 10.06 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ALPMY' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 9.31  Med: 16.35 Max: 56.47
Current: 10.06
9.31
56.47
EV-to-EBIT 9.93
ALPMY's EV-to-EBIT is ranked higher than
85% of the 574 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.65 vs. ALPMY: 9.93 )
Ranked among companies with meaningful EV-to-EBIT only.
ALPMY' s EV-to-EBIT Range Over the Past 10 Years
Min: 0.4  Med: 11.55 Max: 38.6
Current: 9.93
0.4
38.6
EV-to-EBITDA 8.11
ALPMY's EV-to-EBITDA is ranked higher than
86% of the 600 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.72 vs. ALPMY: 8.11 )
Ranked among companies with meaningful EV-to-EBITDA only.
ALPMY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 0.4  Med: 8.8 Max: 38.6
Current: 8.11
0.4
38.6
PEG Ratio 6.28
ALPMY's PEG Ratio is ranked lower than
82% of the 282 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.84 vs. ALPMY: 6.28 )
Ranked among companies with meaningful PEG Ratio only.
ALPMY' s PEG Ratio Range Over the Past 10 Years
Min: 0.57  Med: 1.15 Max: 23.76
Current: 6.28
0.57
23.76
Current Ratio 2.25
ALPMY's Current Ratio is ranked lower than
54% of the 726 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.49 vs. ALPMY: 2.25 )
Ranked among companies with meaningful Current Ratio only.
ALPMY' s Current Ratio Range Over the Past 10 Years
Min: 2.12  Med: 2.57 Max: 3.64
Current: 2.25
2.12
3.64
Quick Ratio 1.85
ALPMY's Quick Ratio is ranked higher than
50% of the 725 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.84 vs. ALPMY: 1.85 )
Ranked among companies with meaningful Quick Ratio only.
ALPMY' s Quick Ratio Range Over the Past 10 Years
Min: 1.72  Med: 2.17 Max: 3.22
Current: 1.85
1.72
3.22
Days Inventory 181.62
ALPMY's Days Inventory is ranked lower than
77% of the 687 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.19 vs. ALPMY: 181.62 )
Ranked among companies with meaningful Days Inventory only.
ALPMY' s Days Inventory Range Over the Past 10 Years
Min: 118.75  Med: 138.57 Max: 181.62
Current: 181.62
118.75
181.62

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.23
ALPMY's Dividend Yield % is ranked higher than
63% of the 623 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.61 vs. ALPMY: 2.23 )
Ranked among companies with meaningful Dividend Yield % only.
ALPMY' s Dividend Yield % Range Over the Past 10 Years
Min: 0.85  Med: 2.51 Max: 4.39
Current: 2.23
0.85
4.39
Dividend Payout Ratio 0.33
ALPMY's Dividend Payout Ratio is ranked higher than
55% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.36 vs. ALPMY: 0.33 )
Ranked among companies with meaningful Dividend Payout Ratio only.
ALPMY' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.19  Med: 0.42 Max: 0.85
Current: 0.33
0.19
0.85
3-Year Dividend Growth Rate 7.20
ALPMY's 3-Year Dividend Growth Rate is ranked lower than
54% of the 285 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.10 vs. ALPMY: 7.20 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
ALPMY' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 1.3  Med: 6.75 Max: 52.5
Current: 7.2
1.3
52.5
Forward Dividend Yield % 2.24
ALPMY's Forward Dividend Yield % is ranked higher than
64% of the 619 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.35 vs. ALPMY: 2.24 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 2.89
ALPMY's 5-Year Yield-on-Cost % is ranked higher than
62% of the 764 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.14 vs. ALPMY: 2.89 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
ALPMY' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.1  Med: 3.25 Max: 5.68
Current: 2.89
1.1
5.68
3-Year Average Share Buyback Ratio 2.00
ALPMY's 3-Year Average Share Buyback Ratio is ranked higher than
96% of the 436 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.40 vs. ALPMY: 2.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ALPMY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -12.8  Med: 2.4 Max: 0
Current: 2
-12.8
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 8.77
ALPMY's Price-to-Net-Current-Asset-Value is ranked lower than
58% of the 542 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. ALPMY: 8.77 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ALPMY' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.2  Med: 4.81 Max: 9.8
Current: 8.77
2.2
9.8
Price-to-Tangible-Book 4.22
ALPMY's Price-to-Tangible-Book is ranked lower than
56% of the 747 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.65 vs. ALPMY: 4.22 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ALPMY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.46  Med: 2.62 Max: 4.87
Current: 4.22
1.46
4.87
Price-to-Intrinsic-Value-Projected-FCF 1.53
ALPMY's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
71% of the 320 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.66 vs. ALPMY: 1.53 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ALPMY' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.5  Med: 1.9 Max: 2.4
Current: 1.53
1.5
2.4
Price-to-Median-PS-Value 1.12
ALPMY's Price-to-Median-PS-Value is ranked higher than
51% of the 703 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.13 vs. ALPMY: 1.12 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ALPMY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.31  Med: 0.98 Max: 4.27
Current: 1.12
0.31
4.27
Price-to-Peter-Lynch-Fair-Value 0.63
ALPMY's Price-to-Peter-Lynch-Fair-Value is ranked higher than
87% of the 168 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.53 vs. ALPMY: 0.63 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
ALPMY' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.42  Med: 1.48 Max: 5.89
Current: 0.63
0.42
5.89
Price-to-Graham-Number 1.71
ALPMY's Price-to-Graham-Number is ranked higher than
62% of the 443 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.25 vs. ALPMY: 1.71 )
Ranked among companies with meaningful Price-to-Graham-Number only.
ALPMY' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.62  Med: 1.42 Max: 2.63
Current: 1.71
0.62
2.63
Earnings Yield (Greenblatt) % 10.09
ALPMY's Earnings Yield (Greenblatt) % is ranked higher than
90% of the 835 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.00 vs. ALPMY: 10.09 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ALPMY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.6  Med: 8.65 Max: 244
Current: 10.09
2.6
244
Forward Rate of Return (Yacktman) % 30.01
ALPMY's Forward Rate of Return (Yacktman) % is ranked higher than
85% of the 358 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.67 vs. ALPMY: 30.01 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ALPMY' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -5.3  Med: 7.3 Max: 30.2
Current: 30.01
-5.3
30.2

More Statistics

Revenue (TTM) (Mil) $12,060
EPS (TTM) $ 0.90
Beta0.48
Short Percentage of Float0.00%
52-Week Range $12.50 - 19.40
Shares Outstanding (Mil)2,056.98
» More Articles for ALPMY

Headlines

Articles On GuruFocus.com
Charles de Vaulx's IVA Funds Semi-Annual Update Call Transcript Sep 27 2016 
Charles De Vaulx Comments on Astellas Pharma Inc. Jun 06 2016 
Charles de Vaulx's Annual IVA Funds Letter from the Portfolio Managers Jun 06 2016 
IVA Worldwide Fund Quarterly Review - Fourth Quarter 2015 Jan 22 2016 
Astellas Pharma: Outstanding Growth, Undervalued Dec 14 2015 
Astellas Pharma Has Been Growing for Years and Is Underpriced Dec 11 2015 
Charles De Vaulx's Q3 2015 IVA Worldwide Fund Commentary Oct 22 2015 
Charles de Vaulx Sells Portions of Three of His Most Valuable Stakes Jun 01 2015 
IVA International Fund Q1 2015 Review May 28 2015 
Charles de Vaulx’s IVA Worldwide Fund Q1 2015 Review May 28 2015 

More From Other Websites
ETFs with exposure to Astellas Pharma, Inc. : February 14, 2017 Feb 14 2017
Astellas Pharma, Inc. :ALPMY-US: Earnings Analysis: Q3, 2017 By the Numbers : February 8, 2017 Feb 08 2017
Astellas Reports the First Nine Months Financial Results of FY2016 Jan 30 2017
Astellas Pharma, Inc. : ALPMY-US: Dividend Analysis : September 29th, 2016 (record date) : By the... Jan 30 2017
Ironwood/Astellas Report Positive Phase III Data on Linzess Jan 30 2017
Astellas and Ironwood Report Positive Top-Line Results from Phase III Linaclotide Trial for Patients... Jan 29 2017
ETFs with exposure to Astellas Pharma, Inc. : January 20, 2017 Jan 20 2017
Astellas to Present at J.P. Morgan Healthcare Conference Dec 21 2016
Astellas Completes Acquisition of Ganymed Pharmaceuticals Dec 21 2016
ETFs with exposure to Astellas Pharma, Inc. : December 19, 2016 Dec 19 2016
Ironwood Pharmaceuticals Announces Approval of LINZESS® (linaclotide) in Japan for the Treatment of... Dec 19 2016
Pfizer and Astellas Announce Top-Line Results from Phase 4 PLATO Trial of XTANDI® (enzalutamide)... Dec 14 2016
ETFs with exposure to Astellas Pharma, Inc. : December 8, 2016 Dec 08 2016
Astellas Research & Development Meeting Highlights Dec 07 2016
GUINNESS WORLD RECORDS™ Title Achieved for Organ Donor Registrations Nov 08 2016
Pharma Stock Roundup: Pfizer, Allergan Q3 Results Fall Short, Insulin Drugmakers under Pricing... Nov 07 2016
ETF’s with exposure to Astellas Pharma, Inc. : November 3, 2016 Nov 03 2016
Astellas Pharma, Inc. :ALPMY-US: Earnings Analysis: Q2, 2017 By the Numbers : November 2, 2016 Nov 02 2016
Astellas to Acquire Ganymed Pharmaceuticals Oct 28 2016
FDA Approves Supplemental New Drug Application for XTANDI® (enzalutamide) Capsules in Advanced... Oct 21 2016
Astellas Pharma Inc. -- Moody's: Japanese pharmaceutical companies' expiring drugs patents could... Oct 19 2016
Astellas Pharma, Inc. : ALPMY-US: Dividend Analysis : March 30th, 2016 (record date) : By the... Oct 14 2016
World Anti-Doping Agency and Astellas Announce Global Initiative to Prevent Misuse and Abuse of... Oct 14 2016
ETF’s with exposure to Astellas Pharma, Inc. : October 11, 2016 Oct 11 2016
Astellas Expands Leadership in Oncology Clinical Development Oct 05 2016
Charles de Vaulx's IVA Funds Semi-Annual Update Call Transcript Sep 27 2016
Astellas Reports First Quarter Financial Results of FY2016 Jul 28 2016
Astellas Launches DigiTx Partners, a Digital Health Investment Company in Partnership with MPM... Jul 28 2016
Excelra Enters into a Drug Repurposing Collaboration with Astellas Pharma Jun 07 2016
Seattle Genetics and Astellas Present ASG-15ME and Enfortumab Vedotin Phase I Clinical Data in... Jun 06 2016
Thunderbolt Pharma, Inc., a Vitesse Biologics Company, Acquires Rights to BAFF/APRIL Dual Antagonist... May 24 2016
Ironwood Pharmaceuticals Announces Filing by Astellas of New Drug Application in Japan with... Feb 24 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK